Sofia Heigis appointed CEO of Oncopeptides
Swedish oncology focused biotech Oncopeptides (Nasdaq Stockholm: ONCO) has announced that its chief executive Monica Shaw will be leaving the company.
As a result, Sofia Heigis, currently chief commercial officer, will take over the role of CEO.
“I am saddened to be leaving Oncopeptides at a time when the promise of Pepaxti [melphalan flufenamide] for patients with multiple myeloma is truly coming to fruition. I am leaving to take up a senior executive role at a large pharmaceutical company but am very glad to be handing over the running of the company to my CCO Sofia Heigis who has been the key driver of the commercialization efforts to date. Sofia will be Oncopeptides CEO as of today and I will secure a smooth transition in the coming weeks. I look forward to seeing the continued growth of Oncopeptides,” said Ms Shaw.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze